Pub Date : 2023-09-13DOI: 10.1038/s41568-023-00610-5
Maria Alieva, Amber K. L. Wezenaar, Ellen J. Wehrens, Anne C. Rios
By providing spatial, molecular and morphological data over time, live-cell imaging can provide a deeper understanding of the cellular and signalling events that determine cancer response to treatment. Understanding this dynamic response has the potential to enhance clinical outcome by identifying biomarkers or actionable targets to improve therapeutic efficacy. Here, we review recent applications of live-cell imaging for uncovering both tumour heterogeneity in treatment response and the mode of action of cancer-targeting drugs. Given the increasing uses of T cell therapies, we discuss the unique opportunity of time-lapse imaging for capturing the interactivity and motility of immunotherapies. Although traditionally limited in the number of molecular features captured, novel developments in multidimensional imaging and multi-omics data integration offer strategies to connect single-cell dynamics to molecular phenotypes. We review the effect of these recent technological advances on our understanding of the cellular dynamics of tumour targeting and discuss their implication for next-generation precision medicine. Live-cell imaging can provide spatial, morphological and molecular understanding of cancer response to treatment. Here, Alieva et al. review its recent application for uncovering drug mode of action and tumour heterogeneity in response to treatment and discuss its application for next-generation precision medicine.
{"title":"Bridging live-cell imaging and next-generation cancer treatment","authors":"Maria Alieva, Amber K. L. Wezenaar, Ellen J. Wehrens, Anne C. Rios","doi":"10.1038/s41568-023-00610-5","DOIUrl":"10.1038/s41568-023-00610-5","url":null,"abstract":"By providing spatial, molecular and morphological data over time, live-cell imaging can provide a deeper understanding of the cellular and signalling events that determine cancer response to treatment. Understanding this dynamic response has the potential to enhance clinical outcome by identifying biomarkers or actionable targets to improve therapeutic efficacy. Here, we review recent applications of live-cell imaging for uncovering both tumour heterogeneity in treatment response and the mode of action of cancer-targeting drugs. Given the increasing uses of T cell therapies, we discuss the unique opportunity of time-lapse imaging for capturing the interactivity and motility of immunotherapies. Although traditionally limited in the number of molecular features captured, novel developments in multidimensional imaging and multi-omics data integration offer strategies to connect single-cell dynamics to molecular phenotypes. We review the effect of these recent technological advances on our understanding of the cellular dynamics of tumour targeting and discuss their implication for next-generation precision medicine. Live-cell imaging can provide spatial, morphological and molecular understanding of cancer response to treatment. Here, Alieva et al. review its recent application for uncovering drug mode of action and tumour heterogeneity in response to treatment and discuss its application for next-generation precision medicine.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 11","pages":"731-745"},"PeriodicalIF":78.5,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10597760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-13DOI: 10.1038/s41568-023-00624-z
Chiara Maria Cattaneo
In this Tools of the Trade article, Chiara Cattaneo describes the development of HANSolo, a high-throughput genetic platform for the personalized identification of CD4+ and CD8+ T cell-recognized (neo)antigens, that can be used to generate patient-specific TCR gene therapies or cancer vaccines.
{"title":"Identification of personalized cancer neoantigens with HANSolo","authors":"Chiara Maria Cattaneo","doi":"10.1038/s41568-023-00624-z","DOIUrl":"10.1038/s41568-023-00624-z","url":null,"abstract":"In this Tools of the Trade article, Chiara Cattaneo describes the development of HANSolo, a high-throughput genetic platform for the personalized identification of CD4+ and CD8+ T cell-recognized (neo)antigens, that can be used to generate patient-specific TCR gene therapies or cancer vaccines.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 12","pages":"800-800"},"PeriodicalIF":78.5,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10597757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-12DOI: 10.1038/s41568-023-00617-y
Emmanuel Olivier
In this Tools of the Trade article, Emmanuel Olivier describes an approach to reprogramming AML cancer cells into induced pluripotent stem cells, which provide faithful genetic models of the most common genetic subgroups of AML.
{"title":"Patient-derived iPSCs to study blood cancer","authors":"Emmanuel Olivier","doi":"10.1038/s41568-023-00617-y","DOIUrl":"10.1038/s41568-023-00617-y","url":null,"abstract":"In this Tools of the Trade article, Emmanuel Olivier describes an approach to reprogramming AML cancer cells into induced pluripotent stem cells, which provide faithful genetic models of the most common genetic subgroups of AML.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 11","pages":"727-727"},"PeriodicalIF":78.5,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-11DOI: 10.1038/s41568-023-00616-z
Julia R. Bauman
An often undervalued skill in science, storytelling is a powerful tool for communicating research to diverse audiences. As scientists, we ought to focus on crafting the narrative of our work: it can effectively convey knowledge to the research community, disseminate findings to lay audiences and help us clarify our own thinking about projects. Although sometimes overlooked, storytelling is a powerful tool for communicating scientific research. In this World View, Julia Bauman outlines what is needed to convey a strong scientific narrative, gleaned from her experience making 60-second TikTok videos summarizing published research papers.
{"title":"Maximize your research impact with storytelling","authors":"Julia R. Bauman","doi":"10.1038/s41568-023-00616-z","DOIUrl":"10.1038/s41568-023-00616-z","url":null,"abstract":"An often undervalued skill in science, storytelling is a powerful tool for communicating research to diverse audiences. As scientists, we ought to focus on crafting the narrative of our work: it can effectively convey knowledge to the research community, disseminate findings to lay audiences and help us clarify our own thinking about projects. Although sometimes overlooked, storytelling is a powerful tool for communicating scientific research. In this World View, Julia Bauman outlines what is needed to convey a strong scientific narrative, gleaned from her experience making 60-second TikTok videos summarizing published research papers.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 12","pages":"799-799"},"PeriodicalIF":78.5,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10212102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-08DOI: 10.1038/s41568-023-00609-y
Matti Poutanen, Malin Hagberg Thulin, Pirkko Härkönen
Sex steroids are major promoters of the growth of breast and prostate cancers. This Review by Poutanen et al. describes the development of treatments for these cancer types that act to restrict sex steroid availability for receptor binding by inhibiting steroid biosynthesis, being a complementary mechanism of action to the more traditional sex steroid antagonists. Sex steroids, such as androgens and oestrogens, are hormones that primarily regulate the physiology of reproductive organs and maintain reproductive capacity in both men and women, respectively. Later in life, these sex steroids can become major promoters of the growth of cancer in the reproductive tissues, such as the breast and prostate, with breast cancer being the most common cancer in women and prostate cancer being the second most common cancer in men. Oestrogens and androgens act via specific receptor proteins that act as steroid-activated transcription factors. Accordingly, all current endocrine therapies for breast and prostate cancer target steroid–receptor interactions either directly or indirectly. These therapies encompass compounds that inhibit gonadotropin-regulated steroid biosynthesis in the gonads, antagonists and degraders of oestrogen and androgen receptors, and inhibitors of enzymes of oestrogen and androgen biosynthesis. Such enzyme inhibitors can reduce the concentration of potent oestrogens and androgens and their precursors in the tumours by blocking their gonadal and adrenal production, by hindering the activation of the blood-transported precursors within the tumours and/or by inhibiting any local de novo steroid biosynthesis in the tumours. Some well-characterized inhibitors of enzymes of the classical biosynthesis routes of oestrogens and androgens are used in the treatment of breast and prostate cancer, and novel compounds are in development. However, it is likely that not all enzymes involved in sex steroid biosynthesis have been discovered. Furthermore, novel biologically active sex steroids, such as 11-oxygenated androgens, have been more recently identified. Accordingly, so-far-unidentified targets and novel mechanisms for inhibiting sex steroid biosynthesis are expected to provide further tools for more efficient therapies for sex steroid-dependent breast and prostate cancer.
{"title":"Targeting sex steroid biosynthesis for breast and prostate cancer therapy","authors":"Matti Poutanen, Malin Hagberg Thulin, Pirkko Härkönen","doi":"10.1038/s41568-023-00609-y","DOIUrl":"10.1038/s41568-023-00609-y","url":null,"abstract":"Sex steroids are major promoters of the growth of breast and prostate cancers. This Review by Poutanen et al. describes the development of treatments for these cancer types that act to restrict sex steroid availability for receptor binding by inhibiting steroid biosynthesis, being a complementary mechanism of action to the more traditional sex steroid antagonists. Sex steroids, such as androgens and oestrogens, are hormones that primarily regulate the physiology of reproductive organs and maintain reproductive capacity in both men and women, respectively. Later in life, these sex steroids can become major promoters of the growth of cancer in the reproductive tissues, such as the breast and prostate, with breast cancer being the most common cancer in women and prostate cancer being the second most common cancer in men. Oestrogens and androgens act via specific receptor proteins that act as steroid-activated transcription factors. Accordingly, all current endocrine therapies for breast and prostate cancer target steroid–receptor interactions either directly or indirectly. These therapies encompass compounds that inhibit gonadotropin-regulated steroid biosynthesis in the gonads, antagonists and degraders of oestrogen and androgen receptors, and inhibitors of enzymes of oestrogen and androgen biosynthesis. Such enzyme inhibitors can reduce the concentration of potent oestrogens and androgens and their precursors in the tumours by blocking their gonadal and adrenal production, by hindering the activation of the blood-transported precursors within the tumours and/or by inhibiting any local de novo steroid biosynthesis in the tumours. Some well-characterized inhibitors of enzymes of the classical biosynthesis routes of oestrogens and androgens are used in the treatment of breast and prostate cancer, and novel compounds are in development. However, it is likely that not all enzymes involved in sex steroid biosynthesis have been discovered. Furthermore, novel biologically active sex steroids, such as 11-oxygenated androgens, have been more recently identified. Accordingly, so-far-unidentified targets and novel mechanisms for inhibiting sex steroid biosynthesis are expected to provide further tools for more efficient therapies for sex steroid-dependent breast and prostate cancer.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 10","pages":"686-709"},"PeriodicalIF":78.5,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10178309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"METTL3 inhibition enhances anti-tumour immunity","authors":"Gabrielle Brewer","doi":"10.1038/s41568-023-00621-2","DOIUrl":"10.1038/s41568-023-00621-2","url":null,"abstract":"In this study, Guirguis et al. show mechanistically how preventing m6A RNA modification through inhibition of METTL3 can promote anti-tumour immunity.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 10","pages":"654-654"},"PeriodicalIF":78.5,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-05DOI: 10.1038/s41568-023-00619-w
Gabrielle Brewer
Rahme et al. establish an in vivo model for low-grade glioma, and use it to demonstrate that Pdgfra insulator loss and Cdkn2a promoter silencing are epigenetic drivers of gliomagenesis.
{"title":"Epigenetic lesions drive gliomagenesis","authors":"Gabrielle Brewer","doi":"10.1038/s41568-023-00619-w","DOIUrl":"10.1038/s41568-023-00619-w","url":null,"abstract":"Rahme et al. establish an in vivo model for low-grade glioma, and use it to demonstrate that Pdgfra insulator loss and Cdkn2a promoter silencing are epigenetic drivers of gliomagenesis.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 10","pages":"653-653"},"PeriodicalIF":78.5,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-04DOI: 10.1038/s41568-023-00620-3
Anna Dart
Bland et al. show that cancer types with heterozygous somatic hotspot mutations in the spliceosome component SF3B1 are vulnerable to PARP inhibition, which causes a defective response to replication stress.
{"title":"Targeting aberrant splicing","authors":"Anna Dart","doi":"10.1038/s41568-023-00620-3","DOIUrl":"10.1038/s41568-023-00620-3","url":null,"abstract":"Bland et al. show that cancer types with heterozygous somatic hotspot mutations in the spliceosome component SF3B1 are vulnerable to PARP inhibition, which causes a defective response to replication stress.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 10","pages":"653-653"},"PeriodicalIF":78.5,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10151509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-30DOI: 10.1038/s41568-023-00618-x
Daniela Senft
Two independent studies published together in Nature find that AT1 cells can have a role in both the initiation and suppression of lung adenocarcinoma.
{"title":"AT1 cells appear centre stage","authors":"Daniela Senft","doi":"10.1038/s41568-023-00618-x","DOIUrl":"10.1038/s41568-023-00618-x","url":null,"abstract":"Two independent studies published together in Nature find that AT1 cells can have a role in both the initiation and suppression of lung adenocarcinoma.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 10","pages":"652-652"},"PeriodicalIF":78.5,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10176990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-29DOI: 10.1038/s41568-023-00614-1
Yuan Ma
In this Tools of the Trade article, Yuan Ma describes the development and use of ARPLA, a spatial imaging tool that can be used to visualize glycoRNAs in single cells, including cancer cells in situ.
在这篇 "贸易工具 "文章中，Yuan Ma 介绍了 ARPLA 的开发和使用情况，这是一种空间成像工具，可用于原位观察单细胞（包括癌细胞）中的糖核糖核酸。
{"title":"ARPLA for spatial imaging of glycoRNAs","authors":"Yuan Ma","doi":"10.1038/s41568-023-00614-1","DOIUrl":"10.1038/s41568-023-00614-1","url":null,"abstract":"In this Tools of the Trade article, Yuan Ma describes the development and use of ARPLA, a spatial imaging tool that can be used to visualize glycoRNAs in single cells, including cancer cells in situ.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 10","pages":"651-651"},"PeriodicalIF":78.5,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10115234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：